Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Buys Selexys As Competitors Stumble In Sickle Cell

Executive Summary

Novartis has exercised its option to acquire Selexys in a deal worth up to $665m, following data from the Phase II SUSTAIN trial of SelG1 in sickle cell disease. The move follows several recent failures in the space.

Advertisement

Related Content

Keeping Track: A Week Of Calm As Shutdown Drags On
GBT Picks Up Inclacumab From Roche's Bargain Bin
Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Emmaus Plans Modest Pricing In 4Q Rollout Of Sickle Cell Drug Endari
Sickle Cell Data Show Value Of Novartis’s Recently Acquired SEG101
Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals
Modus's Intended IPO to Spur Sickle Cell Drug R&D
EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall
Beautiful Mornin' for Oklahoma's Selexys as it bags $665m Novartis option and venture round

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel